Q3 2024 · 13F-HR
Caligan Partners LPholdings as filed
Filed 2024-11-14 · accession 0001420506-24-002574
$315.5M
Reported value
12
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $81.2M | 25.7% | 8,118,592 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $41.3M | 13.1% | 1,436,878 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $39.6M | 12.6% | 1,525,730 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $35.5M | 11.3% | 2,193,488 | Common | SOLE |
| 035255108 | ANIK | ANIKA THERAPEUTICS INC | $35.4M | 11.2% | 1,435,130 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $25.8M | 8.16% | 579,717 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $19.6M | 6.22% | 2,583,585 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $15.7M | 4.98% | 1,195,253 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $11.9M | 3.77% | 981,155 | Common | SOLE |
| 44975P103 | NBP | I MAB | $4.3M | 1.38% | 3,499,330 | Common | SOLE |
| 29251M106 | ENTA | ENANTA PHARMACEUTICALS INC | $3.3M | 1.06% | 322,453 | Common | SOLE |
| 69012T305 | OTLK | OUTLOOK THERAPEUTICS INC | $1.7M | 0.54% | 318,699 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.